DBV Technologies Reports Q2 2026 Financial Results and FDA BLA Progress.
DBV Technologies reported cash and cash equivalents of $174.9 million and continues FDA engagement for the VIASKIN Peanut Patch, anticipating a third-quarter 2026 BLA submission.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day